PatternsRadar
Sign in

ORTINGLOBEORTIN GLOBAL LIMITED

NSE
Full chart
14.39INR+0.57 (+4.12%)Close · 6 Oct 2026
14 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹12 CrMarket cap
—P/E (TTM)
92.8%Delivery

Filings & corporate actions

21 results filed
CSV
Next results · Q2 FY27
Expected 14 Nov 2026 – 16 Nov 2026
Estimate: filed 45–47 days after quarter end, last 4 times
2026
  • 14 AugresultsResults · Q1 FY27 · standalone+0.6%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026-1.3%NSE
  • 30 MayresultsResults · Q4 FY26 · standalone-3.2%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026+4.2%NSE
  • 14 FebresultsResults · Q3 FY26 · standalone+5.0%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-0.1%NSE

Reaction to results · all yearsrose on day 0 in 10 of 21 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2714 Aug 2026+0.6%-3.2%+5.2%0.3×
Q4 FY2630 May 2026-3.2%+28.4%+13.1%0.1×
Q3 FY2614 Feb 2026+5.0%+21.1%+3.4%3.0×
Q2 FY2614 Nov 2025-2.5%+3.4%+17.2%1.0×
Q1 FY2614 Aug 2025-5.0%+6.3%-9.6%0.1×
Q4 FY2526 May 2025-2.3%-5.2%-0.9%0.6×
Q3 FY2512 Feb 2025-0.5%-25.2%-23.3%0.4×
Q2 FY2514 Nov 2024-0.9%-0.3%+0.5%0.2×
Q1 FY2514 Aug 2024+1.0%+6.8%+15.1%0.1×
Q4 FY2431 May 2024+3.2%+2.2%+18.1%2.3×
Q3 FY2417 Feb 2024+0.5%-0.2%-11.4%0.2×
Q2 FY2416 Nov 2023+1.3%+3.4%+11.5%1.5×
Q1 FY2422 Aug 2023+1.0%+1.3%+3.4%0.7×
Q4 FY237 Jun 2023+19.8%+27.6%+13.8%110.9×
Q3 FY2314 Feb 2023-0.7%-0.2%-9.0%0.1×
Q1 FY2322 Aug 2022+0.2%-2.3%+6.1%0.6×
Q4 FY2231 May 2022+0.4%-4.1%-13.2%0.4×
Q3 FY2214 Feb 2022-0.2%-11.4%-11.3%0.5×
Q2 FY2216 Nov 2021-0.9%-3.3%+9.2%0.1×
Q1 FY2214 Aug 2021-5.9%-16.5%-9.7%0.5×
Q4 FY2114 Jul 2021-1.0%-3.6%-13.2%0.2×
Average+0.5%+1.2%+0.7%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-70.9%
Profit YoY—
Interest cost YoY-40.0%
Revenue QoQ-66.3%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue-68.9%—-70.0%———
Profit——————

Key data

CSV
Open13.82
Day range13.80 – 14.51
52-week range10.66 – 21.30
From 52w high-32.4%
RSI (14)43.3
ATR (14)0.91
Volume9.3K
Avg volume (20D)16.0K
Rel volume0.58×
Volatility (1Y)51.9%
Turnover₹1.3L
SMA 50 / 20015.35 / 15.28

Delivery percentage

Latest · 6 Oct 202692.8%
20-day avg75.7%
1-year avg93.8%
Percentile (own history)71st
Range8.0–100.0%
Sessions1,364

Over the last 20 sessions ORTINGLOBE settled 75.7% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 93.8%, so recent sessions are running 18.1 points lower than usual. The latest session ranks higher than 71% of the 1,364 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+4.12%-1.77%-4.19%-15.80%+1.27%+26.23%

Valuation

CSV
Market cap₹12 Cr
P/E (TTM)—
EPS (TTM)-1.11
Shares outstanding81.31L
Listed30 Mar 2021

Ownership

CSV
Promoter1.23%
Promoter Δ QoQ0.00 pp
Public98.77%
FII1.80%
DII0.00%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)0.00.00.00.0
YoY chg-74.5%-63.3%-24.1%-70.9%
Net profit (₹ Cr)(0.5)(0.1)(0.0)(0.3)
YoY chg————
Net margin-3589.3%-432.5%-27.0%-2912.9%
EPS-0.62-0.07-0.01-0.42

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 1.23% · public 98.77%
30 Sept 2021: promoter 15.68%31 Dec 2021: promoter 15.68%31 Mar 2022: promoter 15.68%30 Jun 2022: promoter 15.68%30 Sept 2022: promoter 15.68%31 Dec 2022: promoter 15.68%31 Mar 2023: promoter 21.51%30 Jun 2023: promoter 7.36%30 Sept 2023: promoter 7.37%31 Dec 2023: promoter 7.36%31 Mar 2024: promoter 1.23%30 Jun 2024: promoter 1.23%30 Sept 2024: promoter 1.23%31 Dec 2024: promoter 1.23%31 Mar 2025: promoter 1.23%30 Jun 2025: promoter 1.23%30 Sept 2025: promoter 1.23%31 Dec 2025: promoter 1.23%31 Mar 2026: promoter 1.23%30 Jun 2026: promoter 1.23%
2021-092026-06
  • Promoter
  • Public and others
Promoter
1.23%
Public
98.77%
Promoter change
0.00 pp
Filed
21 Jul 2026
FII
1.80%
DII
0.00%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25AQ4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations0.30.10.10.20.10.00.00.00.00.00.00.0
Other income0.00.00.20.0(0.0)0.00.00.00.00.00.30.0
Total income0.30.10.30.20.10.00.10.10.00.00.30.0
Total expenses1.42.93.50.30.50.20.20.20.50.10.30.4
└ Finance costs0.20.10.10.00.0(0.0)0.00.00.0(0.0)0.00.0
└ Depreciation0.10.10.00.00.00.00.00.00.00.00.00.0
Profit before tax(1.1)(2.8)(3.2)(0.1)(0.5)(0.1)(0.2)(0.2)(0.5)(0.0)(0.0)(0.3)
Tax expense0.0(0.0)1.00.0(0.0)0.00.00.0(0.0)0.00.00.0
Net profit(1.1)(2.8)(4.1)(0.1)(0.5)(0.1)(0.2)(0.2)(0.5)(0.1)(0.0)(0.3)
EPS-1.38-3.43-5.10-0.13-0.58-0.13-0.20-0.22-0.62-0.07-0.01-0.42
Net margin-431.57%-2051.29%-2862.50%-49.38%-862.04%-319.10%-362.25%-440.70%-3589.29%-432.52%-27.03%-2912.93%
PBT margin-425.64%-2062.75%-2194.82%-48.56%-864.23%-302.69%-355.85%-409.30%-3590.00%-398.37%-25.87%-2884.48%
Tax rate————————————

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.

ORTINGLOBE at a glance

  • ORTINGLOBE closed at ₹14.39 on 6 Oct 2026, +4.12% on the day, +26.2% over one year, 32.4% below its 52-week high of ₹21.3.
  • Delivery was 92.8% of traded quantity on 6 Oct 2026, the 71st percentile of its own 1,364 sessions with a reading (20-session average 75.7%, 1-year average 93.8%).
  • Market capitalisation is ₹12 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-1.11).
  • Q1 FY27 results (standalone, filed 14 Aug 2026): revenue ₹0 crore (-70.9% year on year), net profit ₹-0 crore; the price moved +0.6% on the first session after.
  • Promoters held 1.23% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 14 Nov 2026 and 16 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE749B01020
SeriesEQ
Listed30 Mar 2021
History from30 Mar 2021
Sessions1,368

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE